Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper
A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis
Why do some non-smokers get COPD while many heavy smokers don’t?
A new study highlights a strong risk factor for COPD related to lung development
Results of MI4 Emergency COVID-19 Research Funding (Round 2)
RI-MUHC researchers awarded MUHC Foundation funding for a second round of projects with potential impact in a short timeframe
We Care About Rare!
Researchers, advocates and patients gather on Rare Disease Research Day at the RI-MUHC
RI-MUHC investigator joins Global Consortium of Chemosensory Researchers (GCCR) in rapid response to COVID-19
GCCR group develops worldwide survey on smell loss
Results of MI4 Emergency COVID-19 Research Funding (Round 1)
RI-MUHC researchers awarded MUHC Foundation funding for projects with potential impact in a short timeframe
FRQ to create a province-wide COVID-19 Biobank
RI-MUHC researchers take leading roles in the initiative
The Pfizer Investigator Training Program comes to the RI-MUHC!
Clinical research educational training program benefits researchers, staff and students at the inaugural event
Rare respiratory diseases: Combining immunology and respiratory expertise for children and adults
The RI-MUHC is one of eight research centres participating in an NIH-funded project to accelerate the understanding of rare suppurative respiratory diseases...
Pulling out all the stops at the RI-MUHC’s first Open House for prospective trainees
World-renowned researchers. Vibrant learning environment. First-class facilities. If it sounds too good to be true, you weren’t at...